Trastuzumab Effective in Uterine Serous Carcinoma (CME/CE)

08:00 EDT 14 Apr 2018 | MedPageToday

(MedPage Today) -- In patients overexpressing HER2, a 5-month boost in PFS when added to carboplatin-paclitaxel

Original Article: Trastuzumab Effective in Uterine Serous Carcinoma (CME/CE)

More From BioPortfolio on "Trastuzumab Effective in Uterine Serous Carcinoma (CME/CE)"